Gábor Pajkos

3.8k total citations
17 papers, 318 citations indexed

About

Gábor Pajkos is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Gábor Pajkos has authored 17 papers receiving a total of 318 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 5 papers in Molecular Biology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Gábor Pajkos's work include Colorectal Cancer Treatments and Studies (7 papers), Cancer Treatment and Pharmacology (4 papers) and Lung Cancer Research Studies (4 papers). Gábor Pajkos is often cited by papers focused on Colorectal Cancer Treatments and Studies (7 papers), Cancer Treatment and Pharmacology (4 papers) and Lung Cancer Research Studies (4 papers). Gábor Pajkos collaborates with scholars based in Hungary, United States and Spain. Gábor Pajkos's co-authors include István Ember, Katalin Gombos, Róbert Horváth, Lajos Olasz, Krisztina Juhász, János Sándor, István Kiss, Marshall T. Schreeder, Petr Zatloukal and István Albert and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Gábor Pajkos

17 papers receiving 310 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gábor Pajkos Hungary	10	191	118	81	72	46	17	318
Hsiang‐Fong Kao Taiwan	8	208 1.1×	126 1.1×	46 0.6×	108 1.5×	35 0.8×	28	372
Grégoire Marret France	8	119 0.6×	96 0.8×	48 0.6×	74 1.0×	19 0.4×	24	231
Ching-Shan Luo Taiwan	5	124 0.6×	125 1.1×	56 0.7×	84 1.2×	27 0.6×	8	296
Aaron E. Sosa Spain	8	194 1.0×	85 0.7×	30 0.4×	84 1.2×	15 0.3×	13	275
Jiannan Wu China	11	191 1.0×	68 0.6×	162 2.0×	50 0.7×	53 1.2×	18	351
Yonglin Cai China	10	149 0.8×	99 0.8×	93 1.1×	46 0.6×	27 0.6×	30	300
Maria Lucia Iacovino Italy	6	134 0.7×	56 0.5×	35 0.4×	72 1.0×	12 0.3×	13	232
Mykola Onyshchenko United States	8	58 0.3×	191 1.6×	43 0.5×	43 0.6×	105 2.3×	20	360
Francesca Bergomas Italy	6	337 1.8×	76 0.6×	29 0.4×	49 0.7×	23 0.5×	7	469
Nicoletta Provinciali Italy	9	175 0.9×	83 0.7×	119 1.5×	54 0.8×	18 0.4×	22	308

Countries citing papers authored by Gábor Pajkos

Since Specialization

Citations

This map shows the geographic impact of Gábor Pajkos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gábor Pajkos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gábor Pajkos more than expected).

Fields of papers citing papers by Gábor Pajkos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gábor Pajkos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gábor Pajkos. The network helps show where Gábor Pajkos may publish in the future.

Co-authorship network of co-authors of Gábor Pajkos

This figure shows the co-authorship network connecting the top 25 collaborators of Gábor Pajkos. A scholar is included among the top collaborators of Gábor Pajkos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gábor Pajkos. Gábor Pajkos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Förster, Martin, Magnus T. Dillon, Judit Kocsis, et al.. (2019). Patritumab or placebo, with cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: A randomised phase II study. European Journal of Cancer. 123. 36–47. 22 indexed citations

Giralt, J., Yungan Tao, Rolf‐Dieter Kortmann, et al.. (2019). Randomized Phase 2 Trial of a Novel Clonidine Mucoadhesive Buccal Tablet for the Amelioration of Oral Mucositis in Patients Treated With Concomitant Chemoradiation Therapy for Head and Neck Cancer. International Journal of Radiation Oncology*Biology*Physics. 106(2). 320–328. 21 indexed citations

Bondarenko, Igor, Óscar Juan, Gábor Pajkos, et al.. (2018). Preliminary efficacy of durvalumab plus tremelimumab in platinum-refractory/resistant ED-SCLC from arm A of the phase II BALTIC study. Annals of Oncology. 29. viii596–viii596. 27 indexed citations

Horváth, Zsolt, Katalin Boér, Magdolna Dank, et al.. (2016). [Systemic therapy of breast cancer: practice guideline].. PubMed. 60(3). 241–57. 3 indexed citations

Tao, Yungan, J. Giralt, Rajesh V. Lalla, et al.. (2016). PO-0636: Safety profile support efficacy of gingival clonidine tablet to prevent severe oral mucositis in HNC. Radiotherapy and Oncology. 119. S297–S298. 2 indexed citations

Giralt, J., Yungan Tao, René‐Jean Bensadoun, et al.. (2015). Mucoadhesive clonidine (Clonidine Lauriad) in the prevention of severe radiomucositis in head and neck cancer patients: A phase II randomized trial.. Journal of Clinical Oncology. 33(15_suppl). 6058–6058. 5 indexed citations

Langer, Corey J., István Albert, Helen J. Ross, et al.. (2014). Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer. Lung Cancer. 85(3). 420–428. 55 indexed citations

Gombos, Katalin, Róbert Horváth, Krisztina Juhász, et al.. (2013). miRNA expression profiles of oral squamous cell carcinomas.. PubMed. 33(4). 1511–7. 71 indexed citations

Gombos, Katalin, et al.. (2011). Effects of isoflurane on Nfκb p65, Gadd45a and Jnk1 expression in the vital organs of CBA/CA mice.. PubMed. 25(2). 241–4. 9 indexed citations

10.

Langer, Corey J., István Albert, L. Johnetta Blakely, et al.. (2011). A randomized phase II study of carboplatin (C) and etoposide (E) with or without pan-BCL-2 antagonist obatoclax (Ob) in extensive-stage small cell lung cancer (ES-SCLC).. Journal of Clinical Oncology. 29(15_suppl). 7001–7001. 14 indexed citations

11.

Láng, István, Zsuzsanna Kahán, Tamás Pintér, et al.. (2010). Az emlőrák belgyógyászati onkológiai (gyógyszeres) kezelése. PubMed. 54(3). 237–254. 4 indexed citations

12.

Bori, Rita, et al.. (2009). Heterogeneity of pT3 Colorectal Carcinomas According to the Depth of Invasion. Pathology & Oncology Research. 15(3). 527–532. 20 indexed citations

13.

Thirion, P., Pascal Piedbois, Marc Buyse, et al.. (2001). Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer. British Journal of Cancer. 84(5). 611–620. 23 indexed citations

14.

Pajkos, Gábor, et al.. (2000). The prognostic value of the presence of mutations at the codons 12, 13, 61 of K-ras oncogene in colorectal cancer.. PubMed. 20(3A). 1695–701. 34 indexed citations

15.

Pajkos, Gábor, et al.. (1999). [Prognostic value of the presence of the mutation of the codons 12, 13 and 61 in K-ras oncogene in colorectal cancer].. PubMed. 140(30). 1673–9. 5 indexed citations

16.

Pajkos, Gábor, et al.. (1998). [Combined therapy of metastatic liver neoplasms: intrahepatic chemoembolization and systemic chemotherapy].. PubMed. 139(17). 1013–7. 2 indexed citations

17.

Pajkos, Gábor, et al.. (1998). [Low-dose leucovorin and interferon-alpha as modulators of 5-fluorouracil for adjuvant chemotherapy of colorectal cancer].. PubMed. 139(26). 1571–5. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact